You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HR+/HER2-breast Cancer Trial (Standard endocrine therapy plus Apatinib)

Not yet recruiting
  • HR+/HER2-breast Cancer
  • Standard endocrine therapy plus Apatinib
  • (no location specified)
Jun 2, 2023

HER2 Mutant NSCLC, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation Trial (ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki,

Not yet recruiting
  • HER2 Mutant Non-small Cell Lung Cancer
  • +3 more
  • (no location specified)
Dec 6, 2022

Breast Cancer, Ovarian Cancer, Breast Tumors Trial in Dnipro, Kyiv (Axitinib)

Enrolling by invitation
  • Breast Cancer
  • +7 more
  • Dnipro, Ukraine
  • +1 more
Jun 17, 2023

HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)

Not yet recruiting
  • HER2-positive Breast Cancer
  • 68Ga/131I-SGMIB-5F7
  • Shanghai, China
    Huashan Hospital
Aug 1, 2023

HER2-positive Advanced Breast Cancer Trial (DP303c, Trastuzumab, Vinorelbine Tartrate)

Not yet recruiting
  • HER2-positive Advanced Breast Cancer
  • (no location specified)
Jun 4, 2023

HER2-Positive Cancer Trial in Wuhan

Active, not recruiting
  • HER2-Positive Cancer
    • Wuhan, Hubei, China
      TongjiHospital
    Sep 7, 2022

    HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)

    Not yet recruiting
    • HER2-positive Advanced Gastric Cancer
    • HER2-positive Gastroesophageal Junction Adenocarcinoma
    • Trastuzumab deruxtecan
    • (no location specified)
    Aug 11, 2023

    Stomach Tumor Trial (Trastuzumab deruxtecan, Afatinib)

    Not yet recruiting
    • Stomach Neoplasm
    • (no location specified)
    Oct 16, 2023

    HER2-HER3 Dimer in Tumour and Blood Samples From HER2 Positive

    Recruiting
    • HER2-positive Breast Cancer
    • Acquisition of blood samples and tumour tissue samples (biopsies)
    • Brighton, United Kingdom
    • +1 more
    Nov 9, 2022

    HER2-positive Breast Cancer, LMD Trial (Tucatinib 150 MG, Trastuzumab, Capecitabine)

    Not yet recruiting
    • HER2-positive Breast Cancer
    • LMD
    • Tucatinib 150 MG
    • +3 more
    • (no location specified)
    Aug 24, 2023

    HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

    Active, not recruiting
    • HER2-positive Breast Cancer
    • PIK3CA analysis
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Feb 20, 2023

    HER-2 Positive Advanced Solid Tumors Trial (D3L-001)

    Not yet recruiting
    • HER-2 Positive Advanced Solid Tumors
    • D3L-001
    • (no location specified)
    Jul 20, 2023

    Breast Tumor Female Trial in Beijing (CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou))

    Recruiting
    • Breast Neoplasm Female
    • CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
    • Beijing, Beijing, China
    • +1 more
    Jul 31, 2023

    t Pathologic Complete Response Observed in HER2 Positive Breast

    Completed
    • HER2+ Breast Cancer
    • Rawalpindi, Punjab, Pakistan
      Rawalpindi Medical University
    Jun 26, 2023

    HER2-positive Advanced Solid Tumors Trial in Shanghai (DP303c)

    Recruiting
    • HER2-positive Advanced Solid Tumors
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Apr 10, 2023

    HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,

    Not yet recruiting
    • HER2-PositiveRecurrent or Metastatic Breast Cancer
    • SHR-A1811 Injection
    • +2 more
    • (no location specified)
    Sep 21, 2023

    Esophageal Squamous Carcinoma, HER-2 Protein Overexpression Trial (RC48+PD-1+platinum-based)

    Not yet recruiting
    • Esophageal Squamous Carcinoma
    • HER-2 Protein Overexpression
    • (no location specified)
    Sep 24, 2023

    HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)

    Recruiting
    • HR Positive HER2 Negative Advanced Breast Cancer
    • Tianjin, China
      天津市肿瘤医院
    May 26, 2023

    Non-Muscle Invasive Bladder Cancer, HER2 Trial (RC48, Tislelizumab)

    Not yet recruiting
    • Non-Muscle Invasive Bladder Cancer
    • HER2
    • (no location specified)
    Jul 16, 2023

    HER2 Gene Mutation Trial in Shanghai (Injection of IAH0968+Gemcitabine+Cisplatin, Gemcitabine+Cisplatin)

    Recruiting
    • HER2 Gene Mutation
    • Injection of IAH0968+Gemcitabine+Cisplatin
    • Gemcitabine+Cisplatin
    • Shanghai, China
      Fudan University Affiliated Zhongshan Hospital
    Aug 7, 2023

    HER2-positive Breast Cancer Trial in Tampa (Dendritic Cell (DC1) Vaccine, Trastuzumab, Pepinemab)

    Recruiting
    • HER2-positive Breast Cancer
    • Dendritic Cell (DC1) Vaccine
    • +3 more
    • Tampa, Florida
      Moffitt Cancer Center
    Dec 28, 2022

    Early On-treatment Transcriptional Profiling as Predictor of

    Recruiting
    • HER2-positive Breast Cancer
    • +2 more
    • Trastuzumab (neoadjuvant)
    • +2 more
    • Hospitalet de Llobregat, Barcelona, Spain
      Institut Català d'Oncologia l'Hospitalet
    Jun 12, 2023

    Esophageal Tumors, Gastric Tumors Malignant, Breast Cancer Trial in Stockholm ([68Ga]Ga-ABY-025 PET, Biopsy and analysis of HER2

    Recruiting
    • Esophageal Neoplasms
    • +3 more
    • [68Ga]Ga-ABY-025 PET
    • Biopsy and analysis of HER2 expression
    • Stockholm, Sweden
      Department of Radiation Physics and Nuclear Medicine, Karolinska
    Nov 25, 2022

    HER2-positive Breast Cancer Trial in Chengdu (Recombinant anti-HER2 humanized mAb conjugate for injection.R&D code: B003.)

    Active, not recruiting
    • HER2-positive Breast Cancer
    • Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    Jan 30, 2023

    Metastatic Cancer, HER2 Gene Mutation Trial in Seoul (Neratinib Maleate)

    Active, not recruiting
    • Metastatic Cancer
    • HER2 Gene Mutation
    • Neratinib Maleate
    • Seoul, Korea, Republic of
      Korea university Guro hospital
    Oct 18, 2023